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Abstract
The cardiovascular disease (C/VD) database is an integrated and clustered information
resource that covers multi-omic studies (microRNA, genomics, proteomics and metabolo-
mics) of cardiovascular-related traits with special emphasis on coronary artery disease
(CAD). This resource was built by mining existing literature and public databases and there-
after manual biocuration was performed. To enable integration of omic data from distinct
platforms and species, a specific ontology was applied to tie together and harmonise multi-
level omic studies based on gene and protein clusters (CluSO) and mapping of orthologous
genes (OMAP) across species. CAD continues to be a leading cause of death in the popula-
tion worldwide, and it is generally thought to be an age-related disease. However, CAD inci-
dence rates are now known to be highly influenced by environmental factors and
interactions, in addition to genetic determinants. With the complexity of CAD aetiology,
there is a difficulty in research studies to elucidate general elements compared to other car-
diovascular diseases. Data from 92 studies, covering 13945 molecular entries (4353 unique
molecules) is described, including data descriptors for experimental setup, study design,
discovery-validation sample size and associated fold-changes of the differentially expressed
molecular features (p-value<0.05). A dedicated interactive web interface, equipped with a
multi-parametric search engine, data export and indexing menus are provided for a user-
accessible browsing experience. The main aim of this work was the development of a data
repository linking clinical information and molecular differential expression in several CVD-
related traits from multi-omics studies (genomics, transcriptomics, proteomics and metabo-
lomics). As an example case of how to query and identify data sets within the database
framework and concomitantly demonstrate the database utility, we queried CAD-associated
studies and performed a systems-level integrative analysis. URL: www.padb.org/cvd
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Introduction
Cardiovascular disease (CVD) encompasses many pathological conditions that lead to an inte-
gral loss in function of the heart, cardiovascular structures and the circulatory system. This
life-threating and highly debilitating condition is responsible for 32% of all total global deaths,
of which more than half,17%, are due to ischemic heart disease (IHD), 10% stroke and nearly
2% due to hypertensive heart disease (HHD) [1].
Atherosclerosis is the leading underlying condition for the establishment of CAD and the
predominant cause of IHD that often leads to myocardial infarction (MI) [2, 3]. CAD in the
clinical manifestation of atherosclerosis refers to chronic inflammation with early and gradual
accumulation over the life-span of lipids and fibrous elements, that form the basis of the ath-
erosclerotic plaque in large and medium-size arteries essential in the transport of oxygen and
nutrients to the heart [2, 4, 5]. In most of the cases the disease remains clinically asymptomatic
during the first decades of its development [6], until the surface of the atherosclerotic plaque
suffers rupture or erosion, causing formation of a thrombus that obstructs the vessel with dep-
rivation of an adequate blood-flow and consequent ischaemic tissue damage [7]. This ulti-
mately leads to severe disease manifestations as myocardial infarction (MI), stroke, or acute
coronary disease (ACD) [8]. CAD is perceived as a complex disease of multifactorial origin
with a strong genetic component and with an estimated familial heritability between 30 to 60%
[9–11]. Despite major improvements in many of the modifiable risk factors, such as smoking
habits, alcohol intake, and total cholesterol amongst Western nations over the years [12], CAD
still remains the main cause for the majority of cardiovascular events [1].
Several low-income countries have started to adopt into their culture the Western-lifestyle,
and with it many of the CVD-modifiable cardio-metabolic risk factors, and therefore is
expected that this will certainly elevate the rate and range of CVD epidemiology globally [13,
14]. The total annual expenditure of CVD, adding-up direct and indirect costs across EU
countries ascends to 210 billion euros, [12] likewise CVD and stroke altogether have an annual
impact over the United States economy of up to 258 billion euros [15].
In the last decade the emergence of high-throughput Omics platforms opened the possibil-
ity to mechanistically understand diseases and diseases stages at the molecular level. These ana-
lytic technologies are able to provide reliable, robust and fast detection of candidate
biomarkers for disease onset and progression [16].
Screening of tissues and body accessible fluid sources for the detection of small (~21-mer),
highly conserved non-coding RNA molecules—miRNAs, that regulate post-transcriptionally
the expression of genes by binding based on sequence complementarity to the 3’-untranslated
regions (3’-UTR) of specific mRNAs [17] and exert degradation or translational repression of
mRNA targets [18], provides another layer of understating over the role and how they confer
robustness to transcriptional programs in cell differentiation, proliferation, survival and in dis-
ease [19].
On the other hand, transcriptomics technologies are of invaluable source by capturing pat-
terns of expression of ribonucleic acid (RNA) transcripts across the genome [20]. Then, assess-
ing gene expression through microarrays, deep sequencing by RNA sequencing (RNA-seq)
[21, 22] and with other complementary whole-genome sequencing platforms [23] offers a way
to identify signature genes related to a certain human condition [21]. Moreover, the study of
the proteome enables the characterization of the potential function of genes asserted by pro-
teins participating in molecular signalling cascades, as catalysts of enzymatic reactions, and in
protein-protein physical interactions within many cellular processes in health and disease [20].
Therefore, detection and quantitation using mass spectrometry (MS)-based proteomics and
combined with traditional gel-based to liquid chromatography (LC) coupled with high-
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resolution tandem mass spectrometry (MS/MS) has become a widely-accepted method for
measurement of proteins. [24, 25].
Metabolites are not only the end-products of enzymatic reactions, but also active partici-
pants in the regulation of the cellular microenvironment, in which changes in abundance at
the intracellular level of metabolite intermediates can promote changes in gene signal trans-
duction [26, 27] and therefore can be used to investigate the general health status [28].
Databases handling high-throughput expression profiles of miRNAs, genes, proteins and
metabolites in pathological conditions and disease stages are still scarce, exceptionally in the
case of general scope transcriptomics repositories such as NCBI Gene Expression Omnibus
(GEO) [29] and EBI Expression Atlas [30]. However, the core source for publicly available
omic data still resides in peer-reviewed publications, therefore we developed a clustered molec-
ular repository for cardiovascular and vascular diseases, C/VD, containing expression profiles
of microRNA, protein and metabolite across tissues, body-accessible fluids, and species
derived of collected experimental data from peer-reviewed research publications and other rel-
evant databases. Additionally, we performed as a show case of the database utility and to illus-
trate potential uses of the data enclosed in our newly established database, a meta-analysis
integrating omics data sets at the pathway level in CAD.
Material and methods
C/VD database construction
Data collection, storage and handling. The content of the C/VD database is based on
manual extraction of data from available literature on the topic of CVD and omics technolo-
gies. We used several search strings in PubMed and Scopus in order to cover the topic as much
as possible (e.g. "Cardiovascular Diseases"[Mesh] AND (miRNA OR genomic� OR proteomic�
OR metabolomic�) NOT review) and filtered to display only studies in English language. Addi-
tional gene and miRNA data sets were retrieved from the Gene Expression Omnibus (GEO)
Database [29]. We kept data in the tabular form and retained information of the original
source for easy data tracking.
Data biocuration. Publication-based molecular identifiers were converted to internal
identifiers of the Pan-omics Analysis Database (PADB) initiative (www.padb.org), which uses
the clustered sequences and orthologs (CluSO) identifiers and an ortholog mapping resource
(OMAP). These internal identifiers allow us to reduce data redundancy found in many multi-
omic studies. Moreover, it ensures that the C/VD database remains fully integrated into other
databases held within the PADB infrastructure.
We only retained statistically significant and differently expressed molecules e.g. raw and/
or adjusted for multi-comparisons p-value <0.05, and fold-change (FC), transcriptomics: |
FC|� 2.0, proteomics and metabolomics: |FC|� 1.3.
Database deployment. C/VD relies on a NoSQL database system based on dynamically
interlinked and pre-assembled HTML files using in-house built software as described else-
where in more detail [31]. Briefly, the generated database relies on a NoSQL-system, whereby
source data is manipulated in spreadsheets and parsed into pre-assembled and interlinked
html files. In C/VD there are three table sources handling data concerning demographics (clin-
ical data), experimental setup descriptors and molecular descriptors. All of these tables follow
the standard database nomenclature and structure, i.e. they are all linked to each other and to
external databases, for instance UniProt/SwissProt [32], ChEBI [33], Entrez GeneID [34],
miRbase [35], Ensembl [36], UniGene [34] and the Online Mendelian Inheritance in Man
(OMIM) database [37]. Thus, in this way the customised parser allows to emulate a database
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system by pre-assembling query outputs by for example grouping based on disease/ tissue/
molecule.
Conversion of the collected data from source tables to html pages that constitute the front-
end of the database was ensured via in-house built software. Interactive controls were also
added to the html tables such as sorting, pagination, multi-column sorting and data export fea-
tures (Excel, PDF, CSV) by incorporating the DataTables plugin [38] for the jQuery JavaScript
library [39].
A search interface was also implemented in the database that relies on the Hypertext Pre-
processor (PHP) [40] scripting language, based on summary tables i.e. rearranged tables that
simplify the underlying queries, therefore allowing fast, enhanced and customised searches
across the database.
Availability and requirements. Home page: Accessible through the PADB portal at
http://www.padb.org/cvddb. Operating system: C/VD is a web-based database thus it is plat-
form independent. Requirements: works in any browser supporting HTML 4.01 and Java.
License: free for academic use, but requires a license for any commercial purposes.
Case study with a C/VD subset: CAD
Data selection, pre-processing and meta-analysis. We selected a subset of C/VD, CAD
data sets of human cohorts, screened in blood as comparison between CAD cases and control
groups in at least two omics technologies. Since, C/VD only handles data below the P-value
cut-off of 0.05, redundant molecular entries within the same study were combined by averag-
ing their expression values and p-values were combined based on the calculation and combi-
nation of intra-studies P-values by using the popular and well-established Fisher’s method
[41]. Other methods exist, but Fisher’s method performs better in our data type setting, since
Stouffer’s method Stouffer [42] requires studies with similar quality, such as sharing the same
detection platform and also requires similar number of missing values.
A vote counting strategy [43] was used to combine molecular information, where differen-
tially expressed (DE) molecules are first selected based on an overall statistical—P-value
threshold defined as P<0.05. Then, dependent on the type of -omics technology/ platform,
different fold-change (FC) cut-offs were applied: genomics, including miRNA and gene
expression |FC|�2.0; proteomics�1.5 and metabolomics |FC|�1.3 to obtain a list of DE mole-
cules for each study. The vote for each molecule can be then calculated as the total number of
times (frequency (%) distribution) it occurred in all DE study lists to be combined. Afterwards,
the final DE molecules list can be selected based upon a set of minimal number of votes. This
simple approach and yet robust for further downstream analysis, outperforms other meta-
analysis methods, since most cannot handle highly heterogeneous data types with a high
degree of missing values. Then, based on the frequency distribution of the molecular regula-
tion directionality (down or up-regulation trends) across three fold-change (FC) cut-offs (|
FC|�1.3, 1.5 and 2.0) observed in microRNA (MIR), gene (mRNA), protein (PRO) and
metabolite (MET) expression data. Prevalence was given to any molecular entity observing fre-
quency�60% in any case of contradictory regulation.
Data dimensionality reduction. Principal component analysis (PCA) and non-metric
multi-dimensional scaling (MDS) analysis were performed in Primer-E (version 6.1.6) [44].
The input data for the PCA was a matrix containing differential expression as log2 fold-change
(log2FC) of each molecular entity (as variables, N = 654; miRNA, protein and metabolite)
across several Omics study types (as samples, N = 75). In this analysis we used molecular data
reported in at least three independent studies; handling of missing data entries was resolved by
setting it to zero. The triangular resemblance matrix required for MDS was based on the
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measure of Euclidean distances. MDS subsets were also generated to visualise in the 2D and
3D space superimposed Omics studies.
Functional enrichment and pathway analysis. The most reported molecular entries of
each type of omic technology were the input for term clustering analysis performed using gene
ontology (GO) annotation including biological process (BP), molecular function (MF) and cel-
lular component (CC); pathway term clustering using the Kyoto encyclopedia of genes and
genomes (KEGG) [45]and WikiPathways [46] annotation built-in ClueGO app [47] for the
Cytoscape [48] network analysis platform. The default parameters were used (or otherwise in-
text specified) with an overall statistical significance value set to P -value<0.05.
Supervised development of a multi-omics integrative molecular model. The develop-
ment of a molecular model in CAD followed an iterative design (Fig 1) involving data collect-
ing, establishment of a multi-omics database, C/VD, meta-analysis, molecular clustering into
GO and pathway terms and analysis of the interactome followed by several iteration swaps
until the finalised output model was reached.
Post-transcriptional regulation by microRNAs (miRNAs) was verified by assigning miR-
NAs-targets interactions using pre-computed target predictions (miRanda-v5 update of 19-07-
2012) [49] and validated (mirTarBase update of 15-06-2016) [50] mRNA/gene targets via the
CluePedia app 1.5.0 [51] and complementary single searches on an ad hoc basis in mirPath
v3.0 [52].
Assessment of transcriptional regulation by transcription factors (TF’s) was ensured by the
use of CyTargetLinker 3.0.1 [53] and GeneMANIA 3.4.1 [54]. Both apps work within the
Cytoscape network analysis platform [48].
Protein-protein physical interactions (PPI’s) were assessed using STRING 1.3.2 [55] by
establishing an overall minimum confidence score of the enrichment to 0.7.
Enzymatic reactions linking metabolites with proteins were derived from the MetScape app
3.1.3 [56] and missing matches were completed with manual searches across KEGG [45] and
Brenda databases [57] on an ad hoc basis.
In each omic layer (miRNA, protein and metabolites) a subroutine concerning convergence
to gene ontology (GO), KEGG [45] or WikiPathways [46] pathway terms was created to ensure
a focus and validity of the model.
Contextualisation of the created model regarding the studied disease, CAD, was ensured by
adding the highest scored gene-disease associations (GDA) from the DisGeNET database [58]
and reconnecting all the molecular interactions.
At the end, the calculated overall fold-changes of all molecules derived from the meta-anal-
ysis were incorporated and colour coded on top of the built network-based model.
The molecular content of the developed model was then tested for over-representation
(hypergeometric test) and pathway topology analysis using KEGG [45] pathway terms from
the web interface of MetaboAnalyst [59].
Results
Database structure and navigation
Navigation through the C/VD database front-end can be either by browsing the study, sample/
demographic, tissue/source or by molecular entry index pages, or alternatively through mole-
cule names, tissue or disease queries in the search interface (S1–S5 Figs).
Statistics and data summary of C/VD
The database consists of 13945 molecule entries (redundant) of which 4353 are unique (non-
redundant) from a collection of 98 manually curated studies of 50 publications related with
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CVD. A summary of the database content using a snippet of the categorical and numeric vari-
ables (Fig 2) allows uncovering data trends amongst the many datasets that C/VD compre-
hends by plotting a histogram-like chart built using the Tableplot R-package [60]. From
observation of the tableplot, the main molecular entries populating the C/VD database corre-
sponds to human, detected in blood, mainly granulocytes and mononuclear cells from
mRNA/gene in coronary heart disease (CHD). On the other hand, amongst all other molecular
entities in C/VD, microRNAs (miRNA) tend to have lower raw p-values and higher fold-
change (FC) values. Additionally, studies handling metabolomics profiling (MET) tend to
have larger number of individuals displayed here as cohort/sample size (N) (Fig 2).
Almost half (48.53%) of the C/VD content (Fig 3A) within a multitude of omics studies
concerns coronary heart disease (CHD), followed by arteriosclerosis, 16.89%, and heart failure,
11.00%, amongst other conditions that fall under the 10% representation within C/VD. Most
conditions are characterised at least by two types of omics technologies, with the exception of
calcinosis, diabetes mellitus, cardiac resynchronization therapy (CRsyT) and stroke (Fig 3A).
Representation of each omics technology type from C/VD by plotting molecular expression
and statistical scores (Fig 3B) helps in the first instance to assess data dispersion/variability and
outlier detection. Here, it can be verified that many data points in proteomics (PRO) and
metabolomics (MET) display a linear rearrangement perpendicular to the y-axis, which corre-
sponds to the overall statistical cut-off selected by the authors in many experimental omics
studies. On the other hand, gene (mRNA) and microRNA (miRNA) differential expression
studies tend to have associated for each molecular entry individual statistical scores, instead of
an overall cut-off (Fig 3B).
The displayed gene/proteins (Fig 3B) with higher fold-change and p-value thresholds such
as RASSF3, XIRP1, SYNPO2L and SEPT7 are involved in cell shape remodelling, PRKCB1,
MMSADHA, GYG1 and SPCS3 have enzymatic properties, TCF4 and BPTF have roles in
transcription and translation (gene regulation), ANKRD46 and KTN1 are transmembrane
proteins functioning as gateways of many substances, and FOLR1 is an anchor element in bio-
logical membranes acting as receptor. Others like MALAT1, TSC22D2 and CCDC197 have
unknown roles. Highly expressed metabolites such as the LysoPC(14:0), a lysophospholipid
with roles in lipid signalling and fatty acid (FA) metabolism; L-arginine an essential amino
acid (AA) with numerous functions within the body; mannitol and N-Acetyl-D-Glucosamine
6-Phosphate (GlcNAc-6-P) are sugars based endogenous metabolites, the first an sugar alcohol
with diuretic functions and the latter is an acylaminosugar. Both are involved in the phospho-
transferase system (PTS) in bacteria what could suggest an association of cardiovascular dis-
ease with metabolites derived from the intestinal microbiota. Regarding microRNAs
expression, hsa-miR-95, hsa-miR-142-5p and hsa-miR-206 have as predicted targets, genes
involved in proteolytic cascades mediated by ubiquitin. Similarly, hsa-miR-208b targets genes
with functional roles in the p53 signalling pathway (Fig 3B).
Fig 1. Supervised development of an integrative multi-omics molecular model in CAD. Coronary artery disease
(CAD) multi-omics data sets retrieved from C/VD regarding molecular entity type, for instance metabolite (MET),
proteins (PRO) and microRNA (miRNA). Molecular entities from the studies were initially ranked by meta-analysis
using a vote-counting approach (frequency assessment), in which statistical scores (p-values) were combined by
implementing Fisher’s method and differential expression of molecules (fold-change) were merged through a
consensus approach. Following the meta-analysis, a combinatorial integration at the systems-level of all molecular
entities concerning modulation of transcriptional activity via assessment of transcription factors (TF’s), post-
transcriptional regulation ascertained by microRNA-gene interactions (computationally predicted and experimentally
validated), protein-protein interactions (PPI’s), evaluation of metabolic flux and regulation via association of gene-
enzyme-reaction-compound and over-representation analysis of gene ontology (GO) terms and KEGG pathways.
Further contextualisation of the disease model was ensured via incorporation of known CAD-gene associations
sourced from the DisGeNET [44] repository.
https://doi.org/10.1371/journal.pone.0207371.g001
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Data dimensionality reduction. The application of data dimension reduction methods
(Fig 4), with principal components analysis (PCA) (Fig 4A) that describes 93.9% of the cumu-
lative variance of PC1 (75.5%) and PC2 (18.4%) generated from the content of the C/VD
Fig 2. Tableplot of the C/VD database. Each column represents a variable and each row (bar) is an aggregate of a fixed number of records,
i.e. a row bin (here equivalent to a molecule entry). The numeric variables (log10 (N), log10 (p-value) and log2 (FC)) are displayed as bar
charts and categorical variables (specie-disease) as stacked percentage bar charts. Disease type was used as the sorting variable. Cohort size
(N), log10(p-value), log2(fold-change(FC)). Species: Homo sapiens (hsa), Mus musculus (mus), Tags: ENZ: enzyme, DIS: disease, SIG:
signalling, INH: inhibitor TF: transcription and translation, gene regulation, TP: transport, storage, endocytosis, exocytosis, vesicles, CS:
Cell shape, MOD: modulator, regulator, MET: metabolite, TM: transmembrane, CHA: chaperone, chaperonin, MIR: microRNA,
SNORNA: small nucleolar RNA, DEV: development, cell growth, differentiation, morphogenesis, CC: cell cycle, RIB: ribosome, CNL:
channel, RCP: receptor, IGG: Immunoglobulin, SCA: scaffolder, docking, adaptor, MHC: major histocompatibility complex component.
https://doi.org/10.1371/journal.pone.0207371.g002
Fig 3. Disease representativity in the C/VD database (A) and volcano plots displaying differential expression in
each molecular entity per type of Omics technology (B). IC10 (2016) disease classification of the content of C/VD
database and relative proportion (%) to Omics studies. Proteomics (PRO), mRNA (gene-array), miRNA (miRNA-
array), and metabolomics (MET). Cardiac Resynchronization Therapy (CRsyT). Each variable pair shows differential
expression across each molecular entity, X-axis represents log2(fold-change) and Y-axis, -log10(p-value). Type of
Omics: Proteomics (PRO), mRNA (gene-array), miRNA (miRNA-array), and metabolomics (MET). The blue filled
data points denotes molecular entities than observe the following thresholds: mRNA, (Log2FC)>1.8 &
Log10pvalue>5.5; miRNA, (Log2FC)>1.8 & Log10pvalue>17; PRO, (Log2FC)>1.5 & Log10pvalue>5 and MET,
(Log2FC)>1.8 & Log10pvalue>5, and the green filled data points the ones than did not observe that condition.
mRNA: Metastasis associated lung adenocarcinoma transcript 1 protein (MALAT1), RAS association domain-
containing protein 3 (RASSF3), Protein kinase C, beta type 1 (PRKCB1), Ankyrin repeat containing protein 46
(ANKRD46), TSC22-related inducible leucine zipper 4 (TSC22D2), Folate receptor alpha precursor (FOLR1), Kinectin
(KTN1), Methylmalonate-semialdehyde dehydrogenase [acylating] (MMSADHA), Transcription factor 4 (TCF4),
Acidic (leucine-rich) nuclear phosphoprotein 32 family member E (ANP32E). PRO: XIN actin-binding repeat-
containing protein 1 (XIRP1), Glycogenin-1 (GYG1), Synaptopodin 2-like protein (SYNPO2L), Signal peptidase
complex subunit 3 (SPCS3), Spectrin repeat containing protein (CCDC197), Septin-7 (SEPT7) and Nucleosome-
remodelling factor subunit BPTF (BPTF).
https://doi.org/10.1371/journal.pone.0207371.g003
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database based on a matrix handling differential expression of each molecular entity per
Omics type as variables and study ID (“Exp”) as samples. The PCA plot shows the score of
each disease case and the loadings of each variable i.e. the molecular elements on the first two
principal components. The greater spatial distance among most of the disease cases that over-
lap in the plot and heart failure (HF) suggests that the latter can be an outlier due mostly to
contribution of microRNA expression, with hsa-miR-208b (BZJ12), hsa-miR-208a (BZJ35),
hsa-miR-125b-1-3p (BZQ81) and hsa-miR-376a-2-5p (BZ615) as main molecular culprits.
The visualisation of the level of resemblance among many CVD disease cases of the highly
overlapped cluster (Fig 4A) by a non-metric multi-dimensional scaling (MDS) method (Fig
4B1 and 4B2) made possible to pairwise compare spatial distances at 2D (Fig 4B1) and 3D (Fig
4B2) among the origin of tissue/ fluid sources, e.g. blood and heart tissue.
Case study with a C/VD subset: CAD
Data sets description. We selected a subset of 21 studies from the C/VD database regard-
ing CAD across miRNA (two studies), protein (nine studies) and metabolite (10 studies)
expression detected in blood of human cohorts (Table 1). Additional description of other clini-
cal parameters such as age, gender, and clinical history of cases and controls is available in S1
File.
The frequency (%) distribution of the regulation (down, up and not regulated) across three
fold-change (FC) thresholds (|FC|>1.3, 1.5 and 2.0) of the most reported (at least two times)
in CAD of microRNA (MIR), protein (PRO) and metabolite (MET) is shown in Table 2. In
any case of contradictory regulation, prevalence was given to any observing frequency�60%.
The expression matrix handling differential expression raw values is available in S1 File.
The 76 most reported molecules in CAD which includes 18 microRNAs, 16 proteins and 42
metabolites (Table 2) were analysed either by gene ontology (GO), for their biological process
(BP), molecular function (MF) and cellular component (CC) and/or Kyoto encyclopedia of
genes and genomes (KEGG-compounds) (Fig 5).
GO cluster analysis using ClueGO (Fig 5A) showed that the most reported proteins in CAD
are primarily involved in the biological regulation of cholesterol transport (negative regulation
(APOC1 and APOC2)) and absorption (intestinal absorption (APOA1 and APO4)), modifica-
tion of the chylomicron composition (APOB, APOC2, APOA1 and APOA4), regulation of
metabolic processes regarding fatty acid biosynthesis (APOC1, positive regulation (ADIPOQ,
APOA1, APOA4 and APOC2)) and cellular detoxification of superoxide radicals via peroxi-
dase activity (APOA4, MPO, GPX3 and PRDX2). These molecules consist mostly of plasma
lipoprotein particles (very-low-density (APOL1, APOC1, APOA4, APOA1, APOC2 and
APOB), low-density (APOA1, APOC2 and APOB) and intermediate-density (APOB, APOC2
and APOA1)). The nine characterized proteins clustered in the network follow a trend of
decreased expression so we can expect the same trend for their associated functions and bio-
logical processes described above. Additionally, ClueGO analysis of proteins reported once
(S6A Fig), and their connectivity based on STRING protein-protein interactions (S6B Fig),
uncovered the PPAR signalling pathway (containing ADIPOQ, FABP1 and APOA1),
Fig 4. Principal components analysis (PCA) of the content of the C/VD database. Data input was a matrix with differential expression of each molecular
entity per Omics type as variables and study ID (“Exp”) as samples. IC10 (2016) disease classification was used as categorical labels. The PCA (a) displays both
the PCA scores, X-axis: PC1 (75.5%), Y-axis: PC2 (18.4%) with the confidence ellipse of 95% surrounding CVD conditions and the PCA loadings with the
molecular variables hsa-miR-208b (BZJ12), hsa-miR-208a (BZJ35), hsa-miR-206 (BZ290), hsa-miR-125b-1-3p (BZQ81) and hsa-miR-376a-2-5p (BZ615)
represented. Visualisation of the level of similarity between CVD conditions of the highly superimposed cluster (a) was achieved by implementing a non-
metric multi-dimensional scaling (MDS) approach in the 2D (b1) and 3D (b2) space. The MDS plot exhibits pairwise dissimilarities as a measure of the
Euclidean distances among data points. Tissue/ fluid sources (blood, heart) are represented as a factor of the MDS analysis.
https://doi.org/10.1371/journal.pone.0207371.g004
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extracellular matrix (ECM)-receptor interaction (ITGB3, SPP1, CD44 and VTN) activation of
the complement and proteolytic coagulation cascades (FGA, FGG, KNG1 and SERPIND1)
clusters and highlighted the importance of the statins pathway with the cluster (APOC2,
LCAT, APOB, APOA4, APOC, APOA1, ADIPOQ and FABP1).
Similarly, compound analysis using the Kyoto encyclopedia of genes and genomes (KEGG-
compounds) in ClueGO (Fig 5B) yielded the processes of biosynthesis of unsaturated fatty
acids (hexadecanoic acid, (8Z,11Z,14Z)-icosatrienoic acid, alpha-linolenic acid, docosahexae-
noic acid and icosanoic acid), steroid hormone biosynthesis (pregnenolone sulfate, cortisol
and DHEA sulfate) and central carbon metabolism (L-tyrosine, L-histidine, L-valine, L-argi-
nine and glycine) with child elements as biosynthesis of amino acids, ABC transporters, ami-
noacyl-tRNA biosynthesis and involved in protein digestion and absorption. Most of the
metabolites, nine out of thirteen were found decreased in expression (exception for L-valine,
L-arginine, cortisol and DHEA sulfate) so one can expect the same trend for their associated
biological and metabolic processes.
Following the rationale that microRNAs exert post-transcriptional regulation upon
mRNA/gene targets, thereby inversely regulated miR-target pairs can contribute to either an
increased or decreased expression of the target. Therefore, based on the network cluster (Fig
5C) that connects microRNAs-targets via miRanda target prediction (using the CluePedia
1.5.0 app) to biological processes and molecular functions and observing the regulation trend
of microRNAs in Table 2, we can verify that 10 out of 13 microRNAs displayed in the network
are decreased in expression (exception for miR-579, let-7c and miR-943), thus one can expect
Table 1. Dataspace description of CAD studies, from experimental design to clinical information. Human studies and detected in blood. ICD-10[2016] (Atheroscle-
rotic heart disease|I25.1), ICD-10_Parent[2016](Chronic ischaemic heart disease|I25), MeSH_name (Coronary Artery Disease), MeSH_parent (Coronary Disease); Illu-
mina Human v2 MicroRNA expression beadchip (IlluHSAv2MirRNA]; Searchlight Protein Array System (Searchlight ProtArray); Agilent-028004 SurePrint G3 Human
GE 8x60K Microarray (AG-G3 HSAGE8x60K); TaqMan Open Array Human MicroRNA panel (TaqMan OpenHSA), studies statistical score threshold: p-, q-value, FDR
<0.05; high-density lipoprotein (HDL); blood pressure (BP); Body-mass-index (BMI); Males (M), Females (F); coronary artery disease (CAD), coronary disease (CD),
acute myocardial infarction (AMI), stable angina (SA), unstable angina (UA), Non-obstructive coronary atherosclerosis (NOCA), normal coronary artery (NCA), type 2
diabetic coronary heart disease (T2DM-CHD), coronary atherosclerosis (CAS).
Study type compartment Ntotal disease case disease control detection method
Exp25790721 MET plasma 18 CAD healthy LC-MS/MS
Exp26932197a 102 CHD HPLC-MS
Exp27394176a serum 109 CAD UPLC-QTOF/MS
Exp27470195a plasma 43 T2DM-CHD 1D-1H-NMR
Exp27634119a 392 NOCA normal coronary artery LC-QTOF-MS
Exp27634119k 1086 significant CAD non-significant CAD
Exp28414761c 15 stable CAD, time of
catheterization, T0
stable CAD, time of catheterization, >3
months
UPLC-MS/MS and GC-MS
Exp28414761f 15 stable CAD, time of
catheterization, T6
Exp28924163 120 early-stage CAS angiographically normal LC-QTOF/MS
Exp29127404 300 severe obstructive CHD UHPLC-QTOF/MS
Exp22022480 miRNA platelets 24 premature CAD healthy miRNA-array
[IlluHSAv2MirRNA]
Exp28205634 plasma 6 CAD miRNA-array [TaqMan
OpenHSA]
Exp23216991 PRO serum 354 insignificant CAD Searchlight ProtArray
Exp24859250 plasma 20 CHD healthy nanoLC-MS/MS
Exp27350024a1-a5 4 CAD discovery phase MALDI-TOF/TOF
Exp27350024b 40 CAD verification phase ELISA
Exp27350024c 506 CAD validation phase
https://doi.org/10.1371/journal.pone.0207371.t001
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Table 2. Most reported molecular entities in CAD. Overall reported p-value<0.05 and frequency (%) of their differential expression/regulation (DOWN or UP) in each
threshold group. Not regulated (NR). Fold-change (FC). MIR: microRNA, TP: transport, storage, endocytosis, exocytosis, vesicles, CS: Cell shape (cytoskeleton, cell adhe-
sion, morphology, cell junction, cellular structures, extracellular matrix), DIS: disease, ENZ: enzyme, enzymatic properties, INH: inhibitor (protease, kinase, other
enzymes, pathways), and MET: metabolite.
Frequency (%) regulation Reported Tag
|FC|>1.3 |FC|>1.5 |FC|>2.0
Name DOWN UP NR DOWN UP NR DOWN UP NR
hsa-mir-144 50 0 50 0 0 100 0 0 100 2 MIR
hsa-miR-505-3p 50 0 50 0 0 100 0 0 100 2
hsa-let-7c 0 50 50 0 50 50 0 50 50 2
hsa-mir-1303 0 50 50 0 50 50 0 50 50 2
hsa-mir-1305 0 50 50 0 50 50 0 50 50 2
hsa-mir-943 0 50 50 0 50 50 0 50 50 2
hsa-miR-579-3p 0 50 50 0 50 50 0 50 50 2
hsa-miR-10a-5p 50 50 0 50 0 50 50 0 50 2
hsa-mir-362 50 0 50 50 0 50 50 0 50 2
hsa-mir-20a 50 0 50 50 0 50 50 0 50 2
hsa-mir-576 50 50 0 50 0 50 50 0 50 2
hsa-miR-106b-5p 100 0 0 50 0 50 50 0 50 2
hsa-miR-517a-3p 100 0 0 50 0 50 50 0 50 2
hsa-mir-636 50 0 50 50 0 50 50 0 50 2
hsa-mir-661 50 0 50 50 0 50 50 0 50 2
hsa-mir-132 50 50 0 50 0 50 50 0 50 2
hsa-miR-21-5p 50 0 50 50 0 50 50 0 50 2
hsa-miR-1255b-5p 50 0 50 50 0 50 50 0 50 2
APOB 28.6 0 71 14.3 0 86 0 0 100 7 TP PRO
APOA4, ApoA-IV, APOA-IV 66.7 0 33 16.7 0 83 16.7 0 83 6 TP
TMSB4X, TB4X, THYB4 0 80 20 0 80 20 0 60 40 5 CS
APCS, PTX2 80 0 20 60 0 40 40 0 60 5 DIS
ADIPOQ, ACDC, ACRP30 60 0 40 0 0 100 0 0 100 5 CS
APOA1 80 0 20 60 0 40 0 0 100 5 TP
PRDX2, NKEFB, TDPX1 0 0 100 0 0 100 0 0 100 4 ENZ
APOC2, APC2 33.3 33 33 33.3 33 33 0 0 100 3 TP
VTN 0 67 33 0 0 100 0 0 100 3 CS
GPX3, GPXP 33.3 0 67 33.3 0 67 33.3 0 67 3 ENZ
APOC1, APOC1B 33.3 0 67 33.3 0 67 33.3 0 67 3 TP
ACTG1, ACTG 0 100 0 0 100 0 0 50 50 2 CS
ALB, GIG20, GIG42 0 0 100 0 0 100 0 0 100 2 TP
AMBP, ITIL, HCP 0 100 0 0 50 50 0 0 100 2 INH
APOL1, APOL 50 0 50 50 0 50 0 0 100 2 TP
MPO 50 50 0 50 0 50 50 0 50 2 ENZ
(Continued)
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that their targets would be increased in expression, so as their associated biological process.
Specifically, as seen with miR-661, miR-20a-5p and miR-106b-5p that have a greater number
Table 2. (Continued)
Frequency (%) regulation Reported Tag
|FC|>1.3 |FC|>1.5 |FC|>2.0
Name DOWN UP NR DOWN UP NR DOWN UP NR
LysoPC(18:2(9Z,12Z)) 75 25 0 0 25 75 0 25 75 4 MET
LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)) 50 25 25 25 25 50 0 25 75 4
LysoPC(18:1(9Z)) 75 25 0 25 25 50 0 25 75 4
LysoPE(0:0/18:2(9Z,12Z)) 75 25 0 0 25 75 0 25 75 4
LysoPC(18:3(9Z,12Z,15Z)) 75 0 25 25 0 75 0 0 100 4
LysoPC(14:0/0:0) 75 0 25 25 0 75 25 0 75 4
LysoPC(18:0) 75 0 25 50 0 50 25 0 75 4
LysoPC(16:1(9Z)/0:0) 100 0 0 50 0 50 25 0 75 4
LysoPE(16:0/0:0) 50 0 50 0 0 100 0 0 100 4
LysoPC(20:4(5Z,8Z,11Z,14Z)) 25 0 75 0 0 100 0 0 100 4
LysoPC(18:4(6Z,9Z,12Z,15Z)) 75 25 0 0 25 75 0 25 75 4
LysoPC(15:0) 66.7 33 0 33.3 33 33 0 33 67 3
Phytosphingosine 66.7 33 0 66.7 0 33 33.3 0 67 3
Palmitic acid 66.7 33 0 33.3 0 67 33.3 0 67 3
LysoPE(0:0/18:0) 33.3 0 67 0 0 100 0 0 100 3
LysoPE(20:4(5Z,8Z,11Z,14Z)/0:0) 0 33 67 0 0 100 0 0 100 3
L-tyrosine 50 50 0 0 0 100 0 0 100 2
Dehydroepiandrosterone sulfate (DHEA) 50 50 0 0 50 50 0 0 100 2
L-arginine 50 50 0 0 50 50 0 50 50 2
LysoPE(18:2(9Z,12Z)/0:0) 50 50 0 0 50 50 0 50 50 2
Alpha-linolenic acid (ALA) 50 50 0 50 0 50 50 0 50 2
N-Palmitoylethanolamide (PEA) 100 0 0 100 0 0 0 0 100 2
Cer(d18:0/16:0) 0 100 0 0 50 50 0 50 50 2
Pregnenolone sulfate 100 0 0 100 0 0 50 0 50 2
PC(16:0/0:0)[rac] 0 0 100 0 0 100 0 0 100 2
PE(21:0/0:0) 0 0 100 0 0 100 0 0 100 2
LysoPC(22:5(7Z,10Z,13Z,16Z,19Z)) 50 0 50 0 0 100 0 0 100 2
L-valine 0 50 50 0 0 100 0 0 100 2
LysoPE(18:1(9Z)/0:0) 100 0 0 0 0 100 0 0 100 2
LysoPE(18:0/0:0) 0 0 100 0 0 100 0 0 100 2
LysoPE(0:0/20:1(11Z)) 50 0 50 0 0 100 0 0 100 2
2-Hydroxybutyric acid 0 50 50 0 0 100 0 0 100 2
L-Acetylcarnitine (ALCAR or ALC) 0 50 50 0 0 100 0 0 100 2
Glycine 50 0 50 0 0 100 0 0 100 2
LysoPE(0:0/22:5(4Z,7Z,10Z,13Z,16Z)) 50 0 50 0 0 100 0 0 100 2
L-histidine 50 0 50 0 0 100 0 0 100 2
LysoPC(22:5(4Z,7Z,10Z,13Z,16Z)) 50 50 0 0 0 100 0 0 100 2
Cortisol 0 50 50 0 50 50 0 50 50 2
Docosahexaenoic acid (DHA) 50 0 50 50 0 50 50 0 50 2
8,11,14-Eicosatrienoic acid (DGLA) 50 0 50 50 0 50 50 0 50 2
Icosanoic acid (eicosanoic acid) 50 50 0 50 0 50 50 0 50 2
1,7-dimethylxanthine (paraxanthine) 50 50 0 50 0 50 50 0 50 2
https://doi.org/10.1371/journal.pone.0207371.t002
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of targets and follow a down-regulation trend, their targets are involved in protein lipidation,
C-acetyltransferase activity, adherens junction organization and cellular biogenic amine cata-
bolic process for the first described microRNA and additionally the PI3-kinase activity and
inner cell mass cell differentiation for the two latter described microRNAs (Fig 5C). Addi-
tional, search of potential affected KEGG pathways in mirPath v3.0 yield the fatty acid biosyn-
thesis pathway (KEGG map, hsa00061), with up-regulated microRNAs, miR-1303 and miR-
1305 targeting FASN.
Fig 5. Exploratory analysis of CAD using the most reported molecular entities. A: Gene ontology (GO) analysis of the proteomics data sets. Biological process (BP),
molecular function (MF) and cell component (CC). Node size of GO/pathway terms corresponds to the number of matched genes/proteins. B: compound analysis using
KEGG pathway maps. C: miRNA analysis of the respective gene target(s) using miRanda predictions. miRNA-targets were then converged onto GO terms. In A:
apolipoprotein A-I (APOA1), adiponectin (ADIPOQ), apolipoprotein C-I (APOC1), apolipoprotein B-100 (APOB), apolipoprotein A-IV (APOA4), myeloperoxidase
(MPO), peroxiredoxin-2 (PRDX2), glutathione peroxidase 3 (GPX3), apolipoprotein C-II (APOC2), and apolipoprotein L1 (APOL1). In B: hexadecanoic acid (palmitic
acid), (8Z,11Z,14Z)-icosatrienoic acid, alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), icosanoic acid (eicosanoic acid), DHEA sulfate (dehydroepiandrosterone
sulfate), pregnenolone sulfate (3beta-Hydroxypregn-5-en-20-one sulfate). In C: phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD),
acetyl-CoA acetyltransferase, mitochondrial WD repeat domain phosphoinositide-interacting protein 4 (WDR45), sperm acrosome membrane-associated protein 4
(SPACA4), sarcosine dehydrogenase, mitochondrial (SARDH), peroxisomal N(1)-acetyl-spermine/spermidine oxidase (PAOX), fibroblast growth factor receptor 2
(FGFR2), 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial (GCAT), acetyl-CoA acetyltransferase, mitochondrial (ACAT1), LIM and senescent cell antigen-like-
containing domain protein 1 (LIMS1), lymphocyte antigen 6H (LY6H), phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD),
urokinase plasminogen activator surface receptor (PLAUR), coiled-coil domain-containing protein 40 (CCDC40), nectin-1 (NECTIN1), PR domain zinc finger protein 14
(PRDM14), transcription factor SOX-17 (SOX17), cadherin-24 (CDH24), sodium/hydrogen exchanger 1 (SLC9A1), ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2
(BST1), and tumor necrosis factor receptor superfamily member 10A (TNFRSF10A).
https://doi.org/10.1371/journal.pone.0207371.g005
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Interactome analysis and network enrichment
We established a global interactome network (Fig 6) starting with the most reported proteins
in CAD, making associations based on protein-protein interactions using STRING app. After-
wards, as a gap-filling approach, the least reported proteins (S1 File) were added, as well as the
highest scored gene associations from the DisGeNET database (S1 File). Furthermore, we
incorporated metabolic associations providing the linkage of gene-enzyme-reaction-metabo-
lite by merging the former network with a metabolic network built in MetScape (S7 Fig), and
described by ClueGO analysis (S8 and S9 Figs). Later, we kept only the most reported and reg-
ulated microRNAs (miRNAs), providing their association with gene targets present in the net-
work via CluePedia. The possible occurrence of other regulatory elements in the recently
developed network such as transcription factors (TF’s) was ensured by the use of CyTargetLin-
ker and GeneMANIA.
This resulted in a densely interconnected network (Fig 6). This network of 136 entries
(expanded full network contains 176 molecular entities, S10 Fig), including molecules known
to be associated with the query-molecules, consists of a sub-expressed apolipoprotein-cluster
(containing APOC1, APOB, APOA4, APOA1, APOC2 and APOL1) and LCAT, a main driver
of the extracellular metabolism of lipoproteins, involvement of the complement and coagula-
tion cascades (FGA, FGG, SERPIND1, KNG1 and VTN), suggesting inflammation being acti-
vated in the original source tissue, and processes including extracellular matrix receptor
interaction (ITGB3, SPP1, CD44 and VTN), biosynthesis of unsaturated fatty acids (hexadeca-
noic acid, (8Z,11Z,14Z)-icosatrienoic acid, alpha-linolenic acid, docosahexaenoic acid, docosa-
pentaenoic acid, icosanoic acid, arachidate and oleate), steroid hormone biosynthesis
(pregnenolone sulfate, cortisol, corticosterone, 11-dehydrocorticosterone and DHEA sulfate),
amino acid metabolism (L-arginine, L-histidine, glycine and L-alanine) transport (ALB,
APCS), cellular detoxification of oxygen species (PRDX2, MPO and GPX3) and actin cytoskel-
eton (CFL1, ITGAD, ITGB3, ACTG1, TMSB4X). Inter-linking molecules suggest an involve-
ment of transcriptional elements such as ATF2, PPARG, PPARA and EGFR, which are
modulators of genes involved in DNA damage, cell proliferation, anti-apoptosis, glucose and
lipid metabolic processes. Additionally, keeping only microRNAs highly expressed and
inversely correlated with targets, yielded regulatory clusters driven by miR-1305 (directly tar-
geting APOA1 and PPARA), miR-let-7c (directly targeting OLFM4, and resulting query-mole-
cules S100A9 and MT-COX2/COX2) and miR-1303 (targeting both resulting query-molecules
IL6ST and FASN).
Analysis of the condensed network of direct interactions between the 136 (or 176 proteins,
full network, S10 Fig) proteins shows the apolipoprotein-cluster containing APOC1, APOB,
APOA4, APOA1, APOC2 and APOL1, also associated with ALB and LCAT, more than three
interactions between IL6, Il10, RETN, CRP, and ADIPOQ and also between FABP1 and the
apolipoprotein-cluster hub APOA1. The latter’s suggests that the peroxisome proliferator-acti-
vated receptor (PPAR) signalling pathway is perturbed in CAD through an association with
APOA1, FABP1 (PPARA), ADIPOQ and RETN (PPARG) (Fig 6). Additional, manual queries
in the C/VD database (human, CAD or atherosclerosis, detected in blood, gene expression
studies, FC>1.5) looking for regulation trends of network molecules with absent regulation,
resulted in decreased levels of PPARG, MT-CO2/COX2, and FASN, confirming the general
trend of the PPAR signalling pathway to be inactivated/supressed/blunted.
Data mining of the DisGeNET database by associated disease clustering having as input the
16 proteins from Table 2 showed association of MPO, APOA1, APOB and ADIPOQ with
myeloperoxidase deficiency, hypertensive disease, hypercholesterolemia, hyperlipidemia and
hypoalphalipoproteinemia. In a similar approach to mine pathway entries in the KEGG
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database, the common denominator was found as hypertrophic cardiomyopathy (HCM,
KEGG entry hsa05410) containing the cluster IL6, ITGB3 and ACTG1 (Table 3), linking it to
the ECM-receptor interaction, renin-angiotensin system JASK-STAT signalling pathway and
TGFbeta-signalling pathway.
Discussion
The C/VD database handles multi-omics and clinical data retrieved from published experi-
mental studies in literature and by mining NCBI Gene Expression Omnibus (GEO) [29]
resources across multi-species and tissue/fluid sources in cardiovascular disease. Systems-level
integration requires not only large-scale data, but mostly comprehensive data at all molecular
levels, thereby owning a resource able to summon all of these elements altogether on a simple,
comparative and clustered platform is of prime importance. Moreover, as C/VD is part of the
Pan-omics Analysis Database (PADB, www.padb.org) framework, its stability over-time and
regular update is ensured, which is a real problem that many databases face after publication.
Fig 6. CAD interactome. Network representation of microRNAs as node triangles, proteins/genes as circles, enzymes displayed as round rectangles, compounds as
hexagons, and reactions shaped as diamonds, labels colour coded as irreversible/directed: orange, reversible/bidirected: purple. Enrichment using protein-protein
physical interactions is derived from STRING with an established minimum confidence score of 0.70. Gene-enzyme-reaction-compound associations were established
using MetScape 3.1.3 and KEGG. MicroRNA-targets associations were derived using miRanda and TarBase. Differential expression is represented as a colour gradation
from blue (decreased expression) to red (increased expression). Node size is proportional to the number of molecules reported within data sets. Some compounds and
microRNAs of the network were removed (based on fold-change criteria) to reduce the complexity of the figure and thereby enhance visualisation. Full network figure is
available in S10 Fig.
https://doi.org/10.1371/journal.pone.0207371.g006
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Databases covering cardiovascular disease molecular data exist, in the vast majority only
covering single-omics derived data, with prevalence for gene-array data sourced from GEO,
furthermore many are either offline or their domain redirects to other unrelated webpages.
Table 3. Over-representation and pathway topology analysis using KEGG pathways terms. The analysis is based on the molecular elements that constitute the interac-
tome of CAD. Topology analysis is based on degree centrality, which measures the number of links that connects to a node within a pathway. Regulation trend (Trend) is
based on differential expression of either �compounds, or ��gene\proteins, or ���both. Down-regulation (#), up-regulation ("), contradictory regulation or not applicable
(NA). General pathway association (class): fatty acids (FA), amino acids (AA), aminoacylation of transfer RNAs (AAcylation), signalling (SIG), energy metabolism
(EMET), vitamin 5 as precursor (Vit5), disease (DIS), immune system (IMM), antioxidants (AntiOx), hormonal (HOR), and cytoskeleton (Cytosk). Gene-centric or
metabolite-centric analysis (|).
Pathway Total Hits P.Value Topology Gene\compound Class Trend
Biosynthesis of unsaturated
fatty acids|hsa01040
22 8 1.34E-07 0.38 [Hexadecanoic acid, (9Z)-Octadecenoic acid, Linoleate, (8Z,11Z,14Z)-
Icosatrienoic acid, Icosanoic acid, (9Z,12Z,15Z)-Octadecatrienoic acid,
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid, (7Z,10Z,13Z,16Z,19Z)-




34 6 6.16E-06 0.13 [LDHAL6A, IL4I1, GSS, LDHA, LDHB, LDHC] AA NA
Aminoacyl-tRNA biosynthesis|
hsa00970
46 8 6.17E-05 0.18 [Glycine, L-Alanine, L-Arginine, L-Phenylalanine, L-Tyrosine,
L-Histidine, L-Valine, L-Threonine]
AAcylation #�
Pyruvate metabolism|hsa00620 41 5 2.42E-04 0.35 [LDHAL6A, LDHA, LDHB, LDHC, LDHAL6B] EMET NA
PPAR signaling pathway|
hsa03320
















65 5 2.06E-03 0.06 [LDHAL6A, LDHA, LDHB, LDHC, LDHAL6B] EMET NA
Pantothenate and CoA
biosynthesis|hsa00770










3.42|0.24 [FASN, OLAH], [Palmitoyl-CoA, Acyl-carrier protein, Hexadecanoic
acid, (9Z)-Octadecenoic acid]
FA #�
Fatty acid elongation|hsa00062 23 3 3.88E-03 0.03 [FASN, OLAH, ACOT2, ACOT4] FA NA
Hypertrophic cardiomyopathy
(HCM)|hsa05410
25 3 4.94E-03 0.88 [IL6, ITGB3, ACTG1] DIS "��
Histidine metabolism|hsa00340 26|16 2|3 5.52E-03|
1.31E-02
0.93|0.67 [HDC, CNDP1], [L-Histidine, Carnosine, Histamine] AA #�
Complement and coagulation
cascades|hsa04610
67 4 1.42E-02 0.11 [FGA, SERPIND1, KNG1, VTN] IMM NA
Valine, leucine and isoleucine
degradation|hsa00280
44 3 2.35E-02 0.17 [IL4I1, BCAT1, BCAT2] AA NA
Valine, leucine and isoleucine
biosynthesis|hsa00290










21 3 2.77E-02 0.85 [beta-Alanine, L-Histidine, Carnosine] AA #�
Steroid hormone biosynthesis|
hsa00140
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CardioGenBase [61] displays gene-array data sourced from literature and GEO and its cur-
rently offline (verified on 05/07/2018), another database comprising literature-based candidate
CAD genes, CADgene, [62] and its database live status is currently offline (verified on 05/07/
2018, redirects to another unrelated web-page), likewise, In-Cardiome [63] deals with own-
private and literature-based gene expression data, as well with clinical associations and drugs;
Chemogenomics [64] is a literature-based database aiming to explore more extensively the
pharmacological side in cardiovascular disease handling protein targets and small ligands, and
is currently online (verified on 05/07/2018), but requires registration; COPaKB [65] mimics
The Human Protein Atlas database [66] with a subset of data regarding cardiovascular disease
and also GEO data, and its live status is online (verified on 05/07/2018).
The generated interactome in coronary disease (CAD) based on initial meta-analysis and
further systems-level integrative analysis of Omics studies covering circulatory levels of pro-
tein, metabolite and microRNA differential expression spotted disturbed profiles in lipid
metabolism, in particular down-regulation of the unsaturated fatty acids (FA) biosynthesis,
down-regulation of cholesterol binding and transport ability shown by the apolipoprotein con-
taining cluster, phosphatidylcholine-sterol acyltransferase (LCAT) and (FABP1), the involve-
ment of the proliferator-activated receptor (PPAR) signalling pathway, with particular
emphasis on the generalised trend for down-regulation of the peroxisome proliferator-acti-
vated receptor gamma (PPARG), fatty acid synthase (FASN) and their enzyme product, hexa-
decanoic acid (palmitic acid). This is in synergy with putative post-transcriptional regulation
of miR-1305 on PPARA and APOA1, a main apolipoprotein cluster network hub, and dual
regulation of miR-1303 and miR-1305 of FASN. On the other hand, indication of up-regula-
tion of molecular elements involved in the extracellular matrix (ECM)-receptor interaction,
inflammation being activated in the original source tissue and cardiac hypertrophy.
Peroxisome proliferator-activated receptors (PPARs) alpha, beta/delta and gamma are
ligand activated transcription factors that share a substantial homology, 60% to 80%, in their
ligand and DNA-binding domains [67], despite playing different roles in the modulation of
energy metabolism [68]. The three PPARs isoforms are expressed in the heart, including vas-
culature of endothelial [69, 70] and smooth muscle cells [71, 72], but their roles in the cardio-
vascular system and outcomes in disease are still not well established due to major inter-study
variability [73]. The activation or repression of the expression of PPARs gene targets is modu-
lated by transactivation or transrepression mechanisms [74], in which binding of ligands to
PPAR leads to the establishment of heterodimers with the nuclear retinoid receptor (RXR), fol-
lowed by translocation of PPAR-RXR-heterodimer-complex to the nucleus, with subsequent
assembling of co-activator (e.g. PPARGC1A) complexes [75] and binding to specific PPAR
response elements (PPREs) in the promotor region of target genes to induce their expression
[70, 76]. In contrast, in the absence of ligands, the PPAR-RXR-heterodimer-complex recruits
co-repressors (e.g. NCOR1 and NCOR2) that repress gene expression in a DNA-binding-inde-
pendent manner. When a ligand is present and binds, PPAR-RXR induces dissociation of the
co-repressors complex and subsequent release of the co-repressor elements [70, 76, 77].
PPARs are implicated in a plethora of cardiovascular disorders such as cardiac hypertrophy,
atherosclerosis and heart failure, and as well in conditions that pose a risk factor, such as diabe-
tes mellitus, obesity, hypertension and dyslipidemia [78].
Activation of PPARA by binding of fibric acid derivatives (fibrates) results in augmented
levels of high-density lipoprotein (HDL) cholesterol, diminished levels of free fatty acids
(FFA), triglycerides, apolipoprotein C-III (APOC3) [71], and reduced inflammatory response
via inhibition of NF-kappaB and transcription factor AP-1 (AP1/JUN) [79, 80]. In the liver,
PPARA is involved in the degradation of fatty acids (FA) through the induction of numerous
genes coding to enzymes participating in mitochondrial and peroxisomal fatty acid (FA)
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oxidation [81]. Furthermore, PPARA regulates gluconeogenesis [82], biotransformation [83]
and cholesterol metabolism processes [83]. Natural occurring PPARA ligands comprise pros-
taglandins, leukotrienes, eicosapentaenoic acid and docosahexaenoic acid [84]. Many synthetic
PPARA ligands were developed for the management of dyslipidaemia, covering several fibrate
drug agonists as gemfibrozil, clofibrate, fenofibrate and bezafibrate [85].
PPARG activation often leads to processes associated with augmented insulin sensitivity,
and perturbance of pancreatic beta-cell function [86], in adipocyte tissue PPARG enables fatty
acid (FA) storage by inducing adipocyte differentiation [87], and up-regulates expression of
the solute carrier family 2, facilitated glucose transporter member 4 (GLUT4/ SLC2A4) and
phosphatidyl-3-kinase (PI3K) [88, 89]. Moreover, PPARG gene targets are associated with adi-
pocyte differentiation, lipid storage and glucose metabolism, including lipoprotein lipase
(LPL), platelet glycoprotein 4 (CD36), cytosolic phosphoenolpyruvate carboxykinase (PCK1),
aquaporin-7 (AQP7) and adiponectin (ADIPOQ) [90]. Many unsaturated fatty acids bind to
PPARG, including linoleic acid (linoleate) and arachidonic acid [89], and several eicosanoids
[82]. PPARG is a known regulator of glucose metabolism, thereby its synthetic ligands includes
many members of the antidiabetic thiazolidinedione (TZD) drug class, glitazones and telmi-
sartan, an antagonist of the type-1 angiotensin II receptor (AGTR1/AT1) used in the treatment
of hypertension [91]. Additionally, monocytes and macrophages can produce PPARG ligands,
capable to induce an anti-inflammatory response and potentiate inflammatory pro-resolving
actions towards repair and return to homeostasis [92].
Post-transcriptional regulators such as hsa-miR-1303, shown up-regulated profile when
human umbilical vein endothelial cells (HUVECs) were exposed to estradiol [93], also a
down-regulation signature of this microRNA when human-induced pluripotent stem cell-
derived cardiomyocytes were exposed to doxorubicin [94]. Furthermore, hsa-miR-1305 levels
in circulating monocytes was found to be increased after acute exercise as a stress signal in
healthy volunteers [95], and hsa-let-7c associated with cardiac hypertrophy [96], and the
mature sequence hsa-let-7c-5p appears to be associated with hyperglycemia in patients with
coronary heart disease (CHD) [97].
Most patients with CAD undertake treatment for clinical management of other CAD risk
factors, such as control of low-density lipoprotein (LDL) cholesterol levels, triglycerides and
blood pressure, and therefore it is likely that the additional treatment can contribute to the
global interactome profile highlighted above. Thus, we should empathise the potential role of
statins (3-hydroxy-methylglutaryl coenzyme A, HMG-CoA reductase inhibitors), a group of
drugs that are widely applied to reduce the level of blood low-density lipoprotein (LDL) cho-
lesterol and triglycerides [98], and also found to increase the expression of PPARGC1A [99], a
co-activator of PPARG. Other agonists as fibrates drugs are able to induce a diminished activ-
ity of LCAT in plasma [100].
The CAD showcase scenario presented here to demonstrate the utility of the C/VD database
has some limitations as it only used data sets screening circulatory molecules in human
cohorts, thereby potential disease mechanisms, disclosed in experimental studies using cell-
lines and animal models mimicking CAD and as well processes mediated in specific tissue-
types could not be fully perceived. Moreover, we selected only data sets dealing with the clini-
cal description of CAD, leaving out early events perceived in conditions such as atherosclerosis
and late diseases such as myocardial infarction, which for a molecular perspective can pose an
incomplete view over all the involved molecular events undergoing this disease, thus leading
to a partial description of CAD.
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Conclusions and future perspectives
The C/VD database can assist either on the development of novel hypotheses in a data-driven
manner or be a source of literature-based knowledge in the cardiovascular research field.
In the CAD showcase, using a combinatorial systems-biology approach based on integra-
tion of data from circulatory molecular expression profiles covering microRNAs, protein and
metabolite, we provide insights into the biological aspects, including summary descriptions by
gene ontology (GO) and pathway terminology, covering mechanistic aspects through recrea-
tion of protein-protein interactions (PPI’s), metabolic reactions, and providing regulatory ele-
ments exerted by transcriptional factors (TF’s) and microRNAs post-transcriptional
regulation. In CAD a global disturbed profile in lipid metabolism, including biosynthesis of
fatty acids (FA), with blunted ability for cholesterol binding and transport, as well as the
involvement of the proliferator-activated receptor (PPAR) signalling pathway, with PPAR iso-
form alpha (PPARA) being potentially post-transcriptionally regulated by miR-1305 and
resulting sub-expression of PPARA target genes, APOA1 and FABP1. Furthermore, indication
of disrupted biological processes with distinct increase in expression of molecular elements
involved in activation of inflammation, extracellular matrix (ECM)-receptor interaction, and
cardiac hypertrophy could be shown.
We foresee regular database updates, populating the C/VD database with more experimen-
tal studies since the cardiovascular research field, particularly large-scale untargeted
approaches, screening body-accessible fluids are currently in high demand.
Supporting information
S1 Fig. Index page of the tissue/source list of the C/VD database. The fields of disease, spe-
cies, number of studies and number of molecules per each tissue/fluid (blood, heart, aorta,
urine) source are described.
(TIF)
S2 Fig. Index page for the omic studies detected in blood tissue/source. The fields of species,
component, number of molecules, disease, and PMID/DOI are described per study.
(TIF)
S3 Fig. Structure of the C/VD database at the study page-view. First headers enclose the
main bibliometric data associated with a research article. The second and third headers are
with respect to the description of the sample itself and several steps in their processing till
reach molecule identification. The fourth header corresponds to the incoming molecules from
the previous step. It lists all the molecules identified in the study with the associated statistical
scores, fold-change and regulation.
(TIF)
S4 Fig. View of the of a specific molecule entry in C/VD database. In the first header is dis-
played the linkage to external databases. Following it we have represented the associated func-
tion and classification and as well our own type of tag for functional classification (derived
from PADB). The third header corresponds to the number of occurrences of the molecule
across all the studies, disease conditions, species, and tissue/fluid source.
(TIF)
S5 Fig. Demographics page-view. Clinical data (demographics page view) is also represented
in the C/VD database and is linked with the study page and vice-versa.
(TIF)
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S6 Fig. Exploratory analysis of CAD using all reported proteins from the many proteomics
data sets. A: Gene ontology (GO) analysis. B: STRING protein-protein interactions with a
minimum confidence score of 0.70. The light blue demarked oval in B denotes proteins from
the hypertrophic cardiomyopathy (HCM) and ECM-receptor interactions ClueGO derived
cluster. WikiPathways (WP), biological process (BP), molecular function (MF) and cell com-
ponent (CC).
(TIF)
S7 Fig. Visualisation of gene-enzyme-reaction-compound associations through MetScape.
Matched compounds and gene nodes are pink colour filled when derived from the C/VD data-
base and grey when from DisGeNET regarding coronary artery disease (CAD) association.
(TIF)
S8 Fig. Composite image of a MetScape enriched network (main cluster) followed by path-
way association in ClueGO (KEGG compounds and pathway terms). Most significant
enriched node terms are displayed darker. Colour filled compounds and proteins/genes are
from CAD datasets (exception for NOS3 that is derived from DisGeNET). To improve net-
work visualisation some ontology terms were removed from the figure, such as protein diges-
tion and absorption: blue stars; biosynthesis of amino acids: orange stars; central carbon
metabolism in cancer: green stars.
(TIF)
S9 Fig. Composite figure representing MetScape enriched network (remaining clusters)
followed by pathway association in ClueGO (KEGG compounds and GO/pathway terms).
Most significant enriched node terms are displayed darker. Colour filled compounds and pro-
teins/genes are from CAD datasets (exception for ACE that is derived from DisGeNET). To
improve network visualisation some ontology terms were removed from the figure, such as
pyruvate metabolism, glucagon signaling pathway, and glycolysis/gluconeogenesis that have a
grey start annotation.
(TIF)
S10 Fig. Full network representation of coronary artery disease (CAD) interactome. Net-
work representation of microRNAs as node triangles, proteins/genes as circles, enzymes dis-
played as round rectangles, compounds as hexagons, and reactions shaped as diamonds, labels
colour coded as irreversible/directed: orange, reversible/bidirected: purple. Enrichment using
protein-protein physical interactions is derived from STRING with an established minimum
confidence score of 0.70. Gene-enzyme-reaction-compound associations were established
using MetScape 3.1.3 and KEGG. MicroRNA-targets associations were derived using miRanda
and TarBase. Differential expression is represented as a colour gradation from blue (decreased
expression) to red (increased expression). Node size is proportional to the number of mole-
cules reported within data sets.
(TIF)
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